Riverside Hospital of Guangxi Zhuang Autonomous Region

The post-coronavirus disease 2019 (COVID-19) pulmonary sequelae have garnered public concern. We conducted a multicenter cross-sectional study in outpatient and health exam populations from 23 clinical centers (including university-affiliated/provincial general hospitals, municipal general hospitals, county hospitals, and specialized hospitals) in China (2019-2023), to assess temporal trends and potential influencing factors in the detection of CT-diagnosed pulmonary nodules, pleural effusion, pneumonia, and suspected lung tumors, cancer and viral pneumonia, clarifying pandemic impacts on lung health. Dynamic comparisons across key phases including initial outbreak, vaccine rollout, population-wide vaccination, and major adjustment of pandemic control policies, were performed. This study analyzed 1,616,750 clinical samples (1,102,605 outpatient, 514,145 health examination; 885,945 males, 730,805 females). Pulmonary nodule detection rose progressively, with surges in 2020-2021 and 2023, plateauing in 2021-2022. Outpatients and males showed steeper increases. University-affiliated/provincial hospitals had sharpest increases vs. municipal and county tiers. Specialized hospitals matched general hospital rates. AI boosted detection rates. CT-suspected lung tumors/cancer remained low and stable, unrelated to nodule trends. These results underscore 2019-2023 pulmonary nodule detection surges linked to SARS-CoV-2 infections and AI adoption. COVID-19 vaccination did not accelerate detection but may have slowed it short-term. Long-term studies on infection, vaccine impacts and pandemic-detected nodules' outcomes are urgently needed.

BackgroundCurrent therapeutic strategies for thin endometrium have inherent limitations, and zero-time exercise (ZTEx), a professionally guided fragmented low-intensity exercise, may serve as a novel adjunctive intervention for its management.MethodsThis was a single-center randomized sham-controlled trial. Eligible patients undergoing ART were randomly divided into an experimental group (receiving ZTEx intervention) and a control group (receiving sham intervention). The ZTEx intervention was delivered over 12 weeks, featuring fragmented, low-intensity exercises under professional guidance. Key indicators of endometrial health—including endometrial thickness and endometrial receptivity-related parameters—were monitored throughout the intervention period.ResultsAfter 12 weeks of intervention, ANCOVA (adjusted for baseline values) revealed that the experimental group had a significantly greater endometrial thickness than the control group (6.67 ± 1.15 mm vs. 5.88 ± 1.17 mm, P < 0.001). Concurrently, multiple endometrial receptivity-related indices improved significantly in the experimental group (all P < 0.05), including uterine artery hemodynamic parameters (pulsatility index [PI], resistance index [RI], systolic/diastolic ratio [S/D]) and vascularization indices (vascularization index [VI], flow index [FI], vascularization-flow index [VFI]).No exercise-related adverse events were reported over the course of the trial, confirming the safety profile of ZTEx.ConclusionsSupported by rigorous statistical analyses, ZTEx effectively enhances endometrial thickness and receptivity in ART patients with thin endometrium. Its key advantages—safety, feasibility, and no need for additional time or equipment—make it a promising adjuvant intervention in clinical ART settings.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00404-026-08385-4.

Parkinson’s disease (PD) is a common neurological disorder. The research has found that G protein-coupled receptors (GPCRs) may affect the pathogenesis of PD. This study aimed to explore the value of GPCRs-related genes (GPCRs-RGs) with PD. In this study, the PD, control samples, and GPCRs-RGs were obtained from the public database. Then, the candidate genes were identified through differential expression genes obtained from differential expression analysis and GPCRs-RGs. Subsequently, biomarkers were obtained through machine learning, expression analysis, and ROC analysis. Notably, the nomogram, regulatory network, and gene set enrichment analysis (GSEA) of biomarkers were explored. In addition, a clustering analysis was adopted based on the biomarkers, and the immune infiltration were analyzed between the clusters. Finally, the expressions of biomarkers were further validated in clinical samples by reverse transcription quantitative PCR (RT-qPCR). This study identified NTSR1 and GPR161 as biomarkers associated with GPCRs and constructed a nomogram with good predictive ability with PD. The GSEA found 26 common pathways, such as oxidative phosphorylation enriched by NTSR1 and GPR161. Furthermore, the PD samples were divided into PD1 and PD2. Biomarkers were upregulated in PD1, while the scores of the 10 immune cells, such as mast cells and monocytes, in PD 1 were lower than PD 2. Finally, six drugs, such as sorafenib, 10 proteins, such as ARRB1 and ARRB2, and 15 miRNAs, such as hsa-miR-140-5p were found to be associated with biomarkers. The RT-qPCR results showed that biomarkers were downregulated in the PD group, which was consistent with the bioinformatics analysis results. NTSR1 and GPR161 were identified as novel biomarkers associated with GPCRs in PD. These might serve as potential therapeutic targets and provide new ideas for disease prevention, diagnosis, and treatment of PD. Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-31148-1.

Coronary microembolization (CME) is a serious cardiovascular complication that causes severe cardiac dysfunction and arrhythmias. Glutathione (GSH) exhaustion-induced oxidative stress is a key contributor to CME. Here, we explore the molecular mechanisms underlying GSH imbalance during CME. We show that CME induces myocardial injury by disturbing GSH homeostasis, which is ameliorated by glutamate-cysteine ligase modifier subunit (GCLM) or glutaminase (GLS) overexpression. Lysine-specific histone demethylase 1A (KDM1A) removes H3K9me1/2 from the promoter regions of GCLM and GLS to promote their epigenetic expression, thereby maintaining GSH homeostasis in CME. KDM1A is ubiquitinated at the K355 site during CME via inhibiting ubiquitin-specific peptidase 16 (USP16)-mediated deubiquitination. Inducible nitric oxide synthase (iNOS) facilitates S-nitrosylation (SNO) of USP16 at the C731 site, contributing to KDM1A ubiquitination and causing GSH imbalance during CME. Altogether, SNO-USP16 inhibition stabilizes the KDM1A protein to epigenetically activate GCLM and GLS, thus maintaining GSH homeostasis and relieving CME-induced myocardial injury.

This study aims to evaluate the impact of the traditional Chinese medicine formula “Pinggan Jiedu Formula” combined with antiretroviral therapy (ART) on the transcriptional and immune status of hepatitis B virus (HBV) in patients with HIV/HBV co-infection. A total of 62 patients with co-infection of HIV/HBV were included in the study and randomly divided into two groups. In the combined treatment group, 31 patients received PGJDP combined with ART treatment for 24 weeks and then continued to receive ART treatment alone. In the control group, 31 cases received ART treatment throughout the course. The study employed real-time quantitative polymerase chain reaction (RT-qPCR) to detect HBV DNA, HIV RNA, HBV RNA and HIV DNA, and to evaluate the viral replication level and transcriptional activity. Flow cytometry was used to detect the count of CD4 + T cells and the CD4/CD8 ratio in peripheral blood, reflecting the immune status of the patients. The level of HBsAg in serum was detected by enzyme-linked immunosorbent assay (ELISA) to monitor the effect of antiviral treatment. Meanwhile, transient elastography was used to detect liver stiffness (LSM) and calculate the FIB-4 index to evaluate the degree of liver fibrosis. The research results show that compared with the control group, the PGJDP combined treatment group significantly reduced the HBV RNA level, significantly decreased the HBsAg level, significantly increased the CD4 + T cell count, and significantly improved the CD4/CD8 ratio. The PGJDP combined treatment group also showed significant improvement in liver fibrosis indicators. In terms of the incidence of abnormal liver function, the PGJDP combined treatment group was significantly lower than the control group. These results suggest that the combination therapy of PGJDP has potential therapeutic benefits in inhibiting HBV transcription and enhancing the immune response. • To evaluate the effects of “Pinggan Jiedu Prescription” (PGJDP) in combination with antiretroviral therapy (ART) on hepatitis B virus (HBV) transcription and immune status in individuals co-infected with human immunodeficiency virus (HIV) and HBV. • PGJDP combination therapy group showed enhanced hepatic protection and a significantly lower incidence of liver function abnormalities. • Providing a novel therapeutic strategy for HIV-HBV co-infected patients through the integration of PGJDP with ART.